Company news
Gt Biopharma, Inc. (NASDAQ:GTBP) news
Gt Biopharma, Inc. news releases on 6ix. Latest, Sep 15, 2026: GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer…
Press releases & updates
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
September 15, 2026
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
September 11, 2026
GT Biopharma Reports Second Quarter 2026 Financial Results
August 14, 2026
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 7, 2026
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
June 1, 2026
GT Biopharma Reports First Quarter 2026 Financial Results
May 15, 2026
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
May 13, 2026
GT Biopharma to Participate in the 38th Annual Roth Conference
March 11, 2026
GT Biopharma : Amendment to Quarterly Report (Form 10-Q/A)
March 6, 2026
GT Biopharma Reports Full Year 2025 Financial Results
March 1, 2026
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
February 17, 2026
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
February 3, 2026
GT Biopharma Announces IND Submission for GTB-5550 TriKE, a B7-H3-targeted natural killer cell engager for B7-H3 expressing solid tumor cancers
January 16, 2026
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
January 15, 2026
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
November 19, 2025
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 14, 2025
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
October 23, 2025
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory CD33 Expressing Hematologic Malignancies
October 9, 2025
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
October 6, 2025
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
GT Biopharma Reports Second Quarter 2025 Financial Results
August 14, 2025
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
August 11, 2025
GT Biopharma Appoints New Member to its Board of Directors
June 13, 2025
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
May 19, 2025
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
March 4, 2025
GT Biopharma Announces Exercise of Warrants
February 25, 2025
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
February 25, 2025
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
January 26, 2025
GT Biopharma Reports Third Quarter 2024 Financial Results
November 13, 2024
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
September 23, 2024
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 13, 2024
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
June 26, 2024
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
May 20, 2024
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
March 25, 2024
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
January 31, 2024
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
December 3, 2023
GT Biopharma Reports Third Quarter 2023 Financial Results
October 31, 2023
GT Biopharma Reports Second Quarter 2023 Financial Results
August 6, 2023
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 14, 2023
GT Biopharma Names Charles J. Casamento to the Board of Directors
May 3, 2023
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 29, 2023
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
December 29, 2022
GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer
December 13, 2022
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 9, 2022
GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting
November 2, 2022
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
October 30, 2022
GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 5, 2022
GT Biopharma Announces Adjournment of Special Shareholders Meeting
October 3, 2022
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
August 29, 2022